[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4E98Z_LIVpaOCZ_43m_hAnILQBx1dKN-pgVSd6arP_s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":52,"rows":59},"Kaiser Permanente",[4],383,false,54,31,15315735,3,337,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Obesity",26,{"name":18,"count":19},"Depression",22,{"name":21,"count":22},"Diabetes Mellitus, Type 2",12,{"name":24,"count":25},"Colorectal Cancer",10,{"name":27,"count":28},"Hypertension",9,{"name":30,"count":28},"Diabetes",{"name":32,"count":33},"Cardiovascular Diseases",8,{"name":35,"count":33},"Diabetes Mellitus",[37,42,47],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04750616","NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial","2025-04-30","Niacinamide",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06710327","Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation","2025-07","Tranexamic Acid",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05309395","Food Prescriptions to Promote Affordable Diets","2026-06-01","FoodRx",[53,54,55,56,57,58],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[60,85,109,133,160,188,206,224,242,269,294,321,339,365,390,417,444,462,487,515,540,566,584,609,634,658,684,711,735,757,779,804,822,844,867,894,920,938,963,987,1005,1032,1057,1081,1104,1131,1149,1172,1209,1227,1245,1263,1281,1299,1317,1335,1353,1371,1389,1407,1434,1452,1483,1501,1526,1554,1572,1596,1620,1644],{"intervention":46,"totalTrials":61,"cells":62},1,{"EARLY_PHASE1":63,"PHASE1":66,"PHASE2":68,"PHASE3":70,"PHASE4":72,"NA":83},{"trials":64,"activeCount":65},[],0,{"trials":67,"activeCount":65},[],{"trials":69,"activeCount":65},[],{"trials":71,"activeCount":65},[],{"trials":73,"activeCount":61,"soonestReadout":45},[74],{"nctId":43,"briefTitle":44,"status":75,"phases":76,"primaryCompletion":45,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":82},"NOT_YET_RECRUITING",[57],"2025-08","2025-01",56,[81],"Benign Prostatic Hyperplasia",[46],{"trials":84,"activeCount":65},[],{"intervention":51,"totalTrials":61,"cells":86},{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":105,"NA":107},{"trials":88,"activeCount":65},[],{"trials":90,"activeCount":65},[],{"trials":92,"activeCount":65},[],{"trials":94,"activeCount":61,"soonestReadout":50},[95],{"nctId":48,"briefTitle":49,"status":96,"phases":97,"primaryCompletion":50,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":104},"RECRUITING",[56],"2027-06-01","2021-08-21",720,[102,103],"Diet, Healthy","Overweight and Obesity",[51],{"trials":106,"activeCount":65},[],{"trials":108,"activeCount":65},[],{"intervention":41,"totalTrials":61,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":127,"PHASE4":129,"NA":131},{"trials":112,"activeCount":65},[],{"trials":114,"activeCount":65},[],{"trials":116,"activeCount":61,"soonestReadout":40},[117],{"nctId":38,"briefTitle":39,"status":96,"phases":118,"primaryCompletion":40,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":126},[55],"2025-06-30","2021-09-13",304,[123,124,125],"Ischemia Reperfusion Injury","Myocardial Injury","Acute Kidney Injury",[41],{"trials":128,"activeCount":65},[],{"trials":130,"activeCount":65},[],{"trials":132,"activeCount":65},[],{"intervention":134,"totalTrials":61,"cells":135},"ICG",{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":158},{"trials":137,"activeCount":65},[],{"trials":139,"activeCount":65},[],{"trials":141,"activeCount":65},[],{"trials":143,"activeCount":65},[],{"trials":145,"activeCount":65},[146],{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":157},"NCT06258486","Ultrasound Guided Inguinal Indocyanine Green Injection to Identify and Pre-emptively Seal Lymphatic Leaks","UNKNOWN",[57],"2026-02","2024-02",100,[155,156],"Lymphocele","Prostate Cancer",[134],{"trials":159,"activeCount":65},[],{"intervention":161,"totalTrials":61,"cells":162},"Black cohosh",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":186},{"trials":164,"activeCount":65},[],{"trials":166,"activeCount":65},[],{"trials":168,"activeCount":65},[],{"trials":170,"activeCount":65},[],{"trials":172,"activeCount":65},[173],{"nctId":174,"briefTitle":175,"status":149,"phases":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT00169299","Herbal Alternatives for Menopause Symptoms (HALT Study)",[57],"2004-09","2001-06",351,[181],"Vasomotor Symptoms Associated With Menopause",[161,183,184,185],"Multibotanical preparation","Multibotanical preparation + dietary soy counseling","Conjugated equine estrogen +\u002F- medroxyprogesterone acetate",{"trials":187,"activeCount":65},[],{"intervention":183,"totalTrials":61,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":204},{"trials":191,"activeCount":65},[],{"trials":193,"activeCount":65},[],{"trials":195,"activeCount":65},[],{"trials":197,"activeCount":65},[],{"trials":199,"activeCount":65},[200],{"nctId":174,"briefTitle":175,"status":149,"phases":201,"completion":177,"start":178,"enrollment":179,"conditions":202,"interventions":203},[57],[181],[161,183,184,185],{"trials":205,"activeCount":65},[],{"intervention":184,"totalTrials":61,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":222},{"trials":209,"activeCount":65},[],{"trials":211,"activeCount":65},[],{"trials":213,"activeCount":65},[],{"trials":215,"activeCount":65},[],{"trials":217,"activeCount":65},[218],{"nctId":174,"briefTitle":175,"status":149,"phases":219,"completion":177,"start":178,"enrollment":179,"conditions":220,"interventions":221},[57],[181],[161,183,184,185],{"trials":223,"activeCount":65},[],{"intervention":185,"totalTrials":61,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":240},{"trials":227,"activeCount":65},[],{"trials":229,"activeCount":65},[],{"trials":231,"activeCount":65},[],{"trials":233,"activeCount":65},[],{"trials":235,"activeCount":65},[236],{"nctId":174,"briefTitle":175,"status":149,"phases":237,"completion":177,"start":178,"enrollment":179,"conditions":238,"interventions":239},[57],[181],[161,183,184,185],{"trials":241,"activeCount":65},[],{"intervention":243,"totalTrials":61,"cells":244},"Bempedoic Acid \u002F Ezetimibe Oral",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":267},{"trials":246,"activeCount":65},[],{"trials":248,"activeCount":65},[],{"trials":250,"activeCount":65},[],{"trials":252,"activeCount":65},[],{"trials":254,"activeCount":65},[255],{"nctId":256,"briefTitle":257,"status":149,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":266},"NCT05263778","Cholesterol Lowering Via Bempedoic Acid\u002FEzetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study",[57],"2023-06","2023-12","2022-03",500,[32,264,265],"NSTEMI","STEMI",[243],{"trials":268,"activeCount":65},[],{"intervention":270,"totalTrials":61,"cells":271},"Medroxyprogesterone 17-Acetate",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":292},{"trials":273,"activeCount":65},[],{"trials":275,"activeCount":65},[],{"trials":277,"activeCount":65},[],{"trials":279,"activeCount":65},[],{"trials":281,"activeCount":65},[282],{"nctId":283,"briefTitle":284,"status":285,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":33,"conditions":289,"interventions":291},"NCT01776203","Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist","TERMINATED",[57],"2014-04","2012-01",[290],"Dysfunctional Uterine Bleeding",[270],{"trials":293,"activeCount":65},[],{"intervention":295,"totalTrials":61,"cells":296},"ombitasvir, paritaprevir\u002Fr, dasabuvir + ribavirin",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":319},{"trials":298,"activeCount":65},[],{"trials":300,"activeCount":65},[],{"trials":302,"activeCount":65},[],{"trials":304,"activeCount":65},[],{"trials":306,"activeCount":65},[307],{"nctId":308,"briefTitle":309,"status":310,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT02461745","Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO","COMPLETED",[57],"2017-05","2015-06",200,[316],"Hepatitis C, Chronic",[295,318],"ombitasvir, paritaprevir\u002Fr, dasabuvir",{"trials":320,"activeCount":65},[],{"intervention":318,"totalTrials":61,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":337},{"trials":324,"activeCount":65},[],{"trials":326,"activeCount":65},[],{"trials":328,"activeCount":65},[],{"trials":330,"activeCount":65},[],{"trials":332,"activeCount":65},[333],{"nctId":308,"briefTitle":309,"status":310,"phases":334,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":335,"interventions":336},[57],[316],[295,318],{"trials":338,"activeCount":65},[],{"intervention":340,"totalTrials":61,"cells":341},"Ledipasvir 90mg\u002FSofosubvir 400mg",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":350,"NA":363},{"trials":343,"activeCount":65},[],{"trials":345,"activeCount":65},[],{"trials":347,"activeCount":65},[],{"trials":349,"activeCount":65},[],{"trials":351,"activeCount":65},[352],{"nctId":353,"briefTitle":354,"status":355,"phases":356,"primaryCompletion":357,"completion":358,"start":359,"enrollment":65,"conditions":360,"interventions":362},"NCT03279133","Ledipasvir\u002FSofosbuvir Treatment for Hepatitis C in HCT Recipients.","WITHDRAWN",[57],"2018-02-16","2018-04-29","2017-09-01",[361],"Hematopoietic Stem Cell Transplantation",[340],{"trials":364,"activeCount":65},[],{"intervention":366,"totalTrials":61,"cells":367},"Ferric Citrate",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":388},{"trials":369,"activeCount":65},[],{"trials":371,"activeCount":65},[],{"trials":373,"activeCount":65},[],{"trials":375,"activeCount":65},[],{"trials":377,"activeCount":65},[378],{"nctId":379,"briefTitle":380,"status":310,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT03079869","Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients",[57],"2019-09-14","2017-05-01",55,[386],"Hyperphosphatemia",[366],{"trials":389,"activeCount":65},[],{"intervention":391,"totalTrials":61,"cells":392},"Icosapent ethyl",{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":415},{"trials":394,"activeCount":65},[],{"trials":396,"activeCount":65},[],{"trials":398,"activeCount":65},[],{"trials":400,"activeCount":65},[],{"trials":402,"activeCount":65},[403],{"nctId":404,"briefTitle":405,"status":285,"phases":406,"primaryCompletion":407,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":414},"NCT04505098","A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults",[57],"2022-12-15","2020-08-07",39600,[411,412,32,413],"Covid19","Atherosclerosis","Upper Respiratory Tract Infections",[391],{"trials":416,"activeCount":65},[],{"intervention":418,"totalTrials":61,"cells":419},"Bivalirudin",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":440,"NA":442},{"trials":421,"activeCount":65},[],{"trials":423,"activeCount":65},[],{"trials":425,"activeCount":65},[],{"trials":427,"activeCount":65},[428],{"nctId":429,"briefTitle":430,"status":285,"phases":431,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":438},"NCT02448550","Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial",[56],"2016-05-06","2016-06-16","2015-05",250,[437],"Percutaneous Coronary Intervention",[418,439],"Unfractionated heparin",{"trials":441,"activeCount":65},[],{"trials":443,"activeCount":65},[],{"intervention":439,"totalTrials":61,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":458,"NA":460},{"trials":447,"activeCount":65},[],{"trials":449,"activeCount":65},[],{"trials":451,"activeCount":65},[],{"trials":453,"activeCount":65},[454],{"nctId":429,"briefTitle":430,"status":285,"phases":455,"primaryCompletion":432,"completion":433,"start":434,"enrollment":435,"conditions":456,"interventions":457},[56],[437],[418,439],{"trials":459,"activeCount":65},[],{"trials":461,"activeCount":65},[],{"intervention":463,"totalTrials":61,"cells":464},"montelukast sodium",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":483,"NA":485},{"trials":466,"activeCount":65},[],{"trials":468,"activeCount":65},[],{"trials":470,"activeCount":65},[],{"trials":472,"activeCount":65},[473],{"nctId":474,"briefTitle":475,"status":310,"phases":476,"completion":477,"start":478,"enrollment":314,"conditions":479,"interventions":482},"NCT00162864","A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease",[56],"2002-04","1999-12",[480,481],"Asthma","COPD",[463],{"trials":484,"activeCount":65},[],{"trials":486,"activeCount":65},[],{"intervention":488,"totalTrials":61,"cells":489},"Budesonide",{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":511,"NA":513},{"trials":491,"activeCount":65},[],{"trials":493,"activeCount":65},[],{"trials":495,"activeCount":65},[],{"trials":497,"activeCount":65},[498],{"nctId":499,"briefTitle":500,"status":355,"phases":501,"primaryCompletion":502,"completion":503,"start":504,"enrollment":65,"conditions":505,"interventions":510},"NCT03519061","Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates",[55,56],"2019-08-30","2019-10-01","2019-08-13",[506,507,508,509],"Chronic Sinus Infection","Chronic Sinusitis","Chronic Sinusitis - Ethmoidal, Posterior","Chronic Sinus Congestion",[488],{"trials":512,"activeCount":65},[],{"trials":514,"activeCount":65},[],{"intervention":516,"totalTrials":61,"cells":517},"Acetaminophen",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":536,"NA":538},{"trials":519,"activeCount":65},[],{"trials":521,"activeCount":65},[],{"trials":523,"activeCount":65},[],{"trials":525,"activeCount":65},[526],{"nctId":527,"briefTitle":528,"status":310,"phases":529,"primaryCompletion":530,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT00325819","Acetaminophen Before Vaccines for Infants Study (AVIS)",[56],"2009-09","2006-05",374,[534],"Fever",[516],{"trials":537,"activeCount":65},[],{"trials":539,"activeCount":65},[],{"intervention":541,"totalTrials":61,"cells":542},"normal saline",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":562,"NA":564},{"trials":544,"activeCount":65},[],{"trials":546,"activeCount":65},[],{"trials":548,"activeCount":65},[],{"trials":550,"activeCount":65},[551],{"nctId":552,"briefTitle":553,"status":285,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT01580618","Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy",[55,56],"2011-09","2008-01",20,[559],"Pleural Effusion",[541,561],"TNK",{"trials":563,"activeCount":65},[],{"trials":565,"activeCount":65},[],{"intervention":561,"totalTrials":61,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":580,"NA":582},{"trials":569,"activeCount":65},[],{"trials":571,"activeCount":65},[],{"trials":573,"activeCount":65},[],{"trials":575,"activeCount":65},[576],{"nctId":552,"briefTitle":553,"status":285,"phases":577,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":578,"interventions":579},[55,56],[559],[541,561],{"trials":581,"activeCount":65},[],{"trials":583,"activeCount":65},[],{"intervention":585,"totalTrials":61,"cells":586},"Oral Prednisone",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":605,"NA":607},{"trials":588,"activeCount":65},[],{"trials":590,"activeCount":65},[],{"trials":592,"activeCount":65},[],{"trials":594,"activeCount":65},[595],{"nctId":596,"briefTitle":597,"status":310,"phases":598,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":604},"NCT00317447","The Efficacy of Oral Steroids in the Treatment of Acute Sciatica",[56],"2004-04","2002-02",160,[603],"Sciatica",[585],{"trials":606,"activeCount":65},[],{"trials":608,"activeCount":65},[],{"intervention":610,"totalTrials":61,"cells":611},"raltegravir",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":630,"NA":632},{"trials":613,"activeCount":65},[],{"trials":615,"activeCount":65},[],{"trials":617,"activeCount":65},[],{"trials":619,"activeCount":65},[620],{"nctId":621,"briefTitle":622,"status":310,"phases":623,"primaryCompletion":624,"completion":530,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT00529243","Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects",[56],"2008-07","2007-09",52,[628],"HIV Infections",[610],{"trials":631,"activeCount":65},[],{"trials":633,"activeCount":65},[],{"intervention":635,"totalTrials":61,"cells":636},"hetastarch",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":654,"NA":656},{"trials":638,"activeCount":65},[],{"trials":640,"activeCount":65},[],{"trials":642,"activeCount":65},[],{"trials":644,"activeCount":65},[645],{"nctId":646,"briefTitle":647,"status":310,"phases":648,"completion":649,"start":177,"enrollment":650,"conditions":651,"interventions":653},"NCT00307138","Hetastarch and Bleeding Complications After Off-Pump Coronary Bypass Surgery",[56],"2005-08",330,[652],"Postoperative Hemorrhage",[635],{"trials":655,"activeCount":65},[],{"trials":657,"activeCount":65},[],{"intervention":659,"totalTrials":61,"cells":660},"Sodium bicarbonate",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":680,"NA":682},{"trials":662,"activeCount":65},[],{"trials":664,"activeCount":65},[],{"trials":666,"activeCount":65},[],{"trials":668,"activeCount":65},[669],{"nctId":670,"briefTitle":671,"status":310,"phases":672,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":679},"NCT00312117","Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate",[56],"2006-02","2006-01",300,[677,678],"Contrast Induced Nephropathy","Kidney Diseases",[659],{"trials":681,"activeCount":65},[],{"trials":683,"activeCount":65},[],{"intervention":685,"totalTrials":61,"cells":686},"NRT patches",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":707,"NA":709},{"trials":688,"activeCount":65},[],{"trials":690,"activeCount":65},[],{"trials":692,"activeCount":65},[],{"trials":694,"activeCount":65},[695],{"nctId":696,"briefTitle":697,"status":310,"phases":698,"primaryCompletion":699,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":706},"NCT00366977","Efficacy and Cost of State Quitline Policies",[56],"2005-01","2000-06",4614,[703,704,705],"Smoking Cessation","Tobacco Use Cessation","Cost-effectiveness",[685],{"trials":708,"activeCount":65},[],{"trials":710,"activeCount":65},[],{"intervention":712,"totalTrials":61,"cells":713},"Alteplase",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":715,"activeCount":65},[],{"trials":717,"activeCount":65},[],{"trials":719,"activeCount":65},[720],{"nctId":721,"briefTitle":722,"status":310,"phases":723,"primaryCompletion":724,"completion":724,"start":673,"enrollment":557,"conditions":725,"interventions":728},"NCT00284739","Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses",[55],"2007-10",[726,727],"Abdominal Abscess","Pelvic Abscess",[712],{"trials":730,"activeCount":65},[],{"trials":732,"activeCount":65},[],{"trials":734,"activeCount":65},[],{"intervention":736,"totalTrials":61,"cells":737},"Oral tinidazole",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":739,"activeCount":65},[],{"trials":741,"activeCount":65},[],{"trials":743,"activeCount":65},[744],{"nctId":745,"briefTitle":746,"status":355,"phases":747,"enrollment":65,"conditions":748,"interventions":750},"NCT00324142","A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis",[55],[749],"Recurrent Bacterial Vaginosis",[736],{"trials":752,"activeCount":65},[],{"trials":754,"activeCount":65},[],{"trials":756,"activeCount":65},[],{"intervention":758,"totalTrials":61,"cells":759},"Abraxane",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":761,"activeCount":65},[],{"trials":763,"activeCount":65},[],{"trials":765,"activeCount":65},[766],{"nctId":767,"briefTitle":768,"status":310,"phases":769,"primaryCompletion":724,"completion":770,"start":649,"enrollment":79,"conditions":771,"interventions":772},"NCT00284752","Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer",[55],"2011-12",[156],[758],{"trials":774,"activeCount":65},[],{"trials":776,"activeCount":65},[],{"trials":778,"activeCount":65},[],{"intervention":780,"totalTrials":61,"cells":781},"ibalizumab 800mg Q2Weeks",{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":783,"activeCount":65},[],{"trials":785,"activeCount":65},[],{"trials":787,"activeCount":65},[788],{"nctId":789,"briefTitle":790,"status":310,"phases":791,"primaryCompletion":792,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":796},"NCT01056393","Investigator-Sponsored Protocol - Continued Use of Ibalizumab",[55],"2016-12-15","2009-11",5,[628],[780,797],"ibalizumab 2000mg Q4Weeks",{"trials":799,"activeCount":65},[],{"trials":801,"activeCount":65},[],{"trials":803,"activeCount":65},[],{"intervention":797,"totalTrials":61,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":816,"PHASE4":818,"NA":820},{"trials":807,"activeCount":65},[],{"trials":809,"activeCount":65},[],{"trials":811,"activeCount":65},[812],{"nctId":789,"briefTitle":790,"status":310,"phases":813,"primaryCompletion":792,"completion":792,"start":793,"enrollment":794,"conditions":814,"interventions":815},[55],[628],[780,797],{"trials":817,"activeCount":65},[],{"trials":819,"activeCount":65},[],{"trials":821,"activeCount":65},[],{"intervention":823,"totalTrials":61,"cells":824},"Candesartan",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":826,"activeCount":65},[],{"trials":828,"activeCount":65},[],{"trials":830,"activeCount":65},[831],{"nctId":832,"briefTitle":833,"status":355,"phases":834,"enrollment":65,"conditions":835,"interventions":837},"NCT00930995","Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C",[55],[836],"Hepatitis C",[823],{"trials":839,"activeCount":65},[],{"trials":841,"activeCount":65},[],{"trials":843,"activeCount":65},[],{"intervention":845,"totalTrials":61,"cells":846},"Misoprostol",{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":848,"activeCount":65},[],{"trials":850,"activeCount":65},[],{"trials":852,"activeCount":65},[853],{"nctId":854,"briefTitle":855,"status":310,"phases":856,"completion":531,"start":857,"enrollment":314,"conditions":858,"interventions":860},"NCT00310921","A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination",[55],"2001-05",[859],"Abortion, Therapeutic",[845],{"trials":862,"activeCount":65},[],{"trials":864,"activeCount":65},[],{"trials":866,"activeCount":65},[],{"intervention":868,"totalTrials":61,"cells":869},"gentamicin sulfate",{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":888,"PHASE4":890,"NA":892},{"trials":871,"activeCount":65},[],{"trials":873,"activeCount":65},[],{"trials":875,"activeCount":65},[876],{"nctId":877,"briefTitle":878,"status":310,"phases":879,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":883,"interventions":887},"NCT04246996","Gentamicin Intravesical Efficacy for Infection of Urinary Tract",[55],"2021-12-05","2020-01-29",370,[884,885,886],"Postoperative Urinary Tract Infection","Pelvic Organ Prolapse","Stress Urinary Incontinence",[868],{"trials":889,"activeCount":65},[],{"trials":891,"activeCount":65},[],{"trials":893,"activeCount":65},[],{"intervention":895,"totalTrials":61,"cells":896},"PCV7, Prevnar®",{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":898,"activeCount":65},[],{"trials":900,"activeCount":65},[],{"trials":902,"activeCount":65},[903],{"nctId":904,"briefTitle":905,"status":310,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT00169234","Pneumococcal Adult-dose Ranging Immunization Study",[54,55],"2005-02","2003-05",220,[911],"Pneumonia",[895,913],"Pneumovax 23",{"trials":915,"activeCount":65},[],{"trials":917,"activeCount":65},[],{"trials":919,"activeCount":65},[],{"intervention":913,"totalTrials":61,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":923,"activeCount":65},[],{"trials":925,"activeCount":65},[],{"trials":927,"activeCount":65},[928],{"nctId":904,"briefTitle":905,"status":310,"phases":929,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":930,"interventions":931},[54,55],[911],[895,913],{"trials":933,"activeCount":65},[],{"trials":935,"activeCount":65},[],{"trials":937,"activeCount":65},[],{"intervention":939,"totalTrials":61,"cells":940},"Prednisone",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":942,"activeCount":65},[],{"trials":944,"activeCount":65},[],{"trials":946,"activeCount":65},[947],{"nctId":948,"briefTitle":949,"status":310,"phases":950,"primaryCompletion":951,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":956},"NCT00668434","Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica",[55],"2012-09","2013-09","2008-11",269,[603],[939],{"trials":958,"activeCount":65},[],{"trials":960,"activeCount":65},[],{"trials":962,"activeCount":65},[],{"intervention":964,"totalTrials":61,"cells":965},"Group A",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":967,"activeCount":65},[],{"trials":969,"activeCount":65},[970],{"nctId":971,"briefTitle":972,"status":355,"phases":973,"primaryCompletion":974,"start":974,"enrollment":65,"conditions":975,"interventions":977},"NCT01920373","Platelet-Rich Plasma vs Corticosteroid Injection as Treatment for Degenerative Pathology of the Temporomandibular Joint",[54],"2013-11",[976],"Degenerative Joint Disease",[964,978],"Group B",{"trials":980,"activeCount":65},[],{"trials":982,"activeCount":65},[],{"trials":984,"activeCount":65},[],{"trials":986,"activeCount":65},[],{"intervention":978,"totalTrials":61,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":65},[],{"trials":992,"activeCount":65},[993],{"nctId":971,"briefTitle":972,"status":355,"phases":994,"primaryCompletion":974,"start":974,"enrollment":65,"conditions":995,"interventions":996},[54],[976],[964,978],{"trials":998,"activeCount":65},[],{"trials":1000,"activeCount":65},[],{"trials":1002,"activeCount":65},[],{"trials":1004,"activeCount":65},[],{"intervention":1006,"totalTrials":61,"cells":1007},"Nicotine patch",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1024,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1009,"activeCount":65},[],{"trials":1011,"activeCount":65},[1012],{"nctId":1013,"briefTitle":1014,"status":310,"phases":1015,"primaryCompletion":1016,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1023},"NCT04560868","Development of a mHealth Intervention for Ambivalent Smokers",[54],"2021-09-27","2020-12-16",57,[1020,703,1021,1022],"Tobacco Use Disorder","Motivation","Behavior, Smoking",[1006],{"trials":1025,"activeCount":65},[],{"trials":1027,"activeCount":65},[],{"trials":1029,"activeCount":65},[],{"trials":1031,"activeCount":65},[],{"intervention":1033,"totalTrials":61,"cells":1034},"Varenicline",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1036,"activeCount":65},[],{"trials":1038,"activeCount":65},[],{"trials":1040,"activeCount":65},[],{"trials":1042,"activeCount":65},[],{"trials":1044,"activeCount":65},[],{"trials":1046,"activeCount":65},[1047],{"nctId":1048,"briefTitle":1049,"status":310,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1056},"NCT02136498","My Mobile Advice Program: A Randomized Pilot Feasibility Study",[58],"2016-02","2014-10",66,[703,1055],"Medication Adherence",[1033],{"intervention":1058,"totalTrials":61,"cells":1059},"Direct Acting Antivirals",{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1061,"activeCount":65},[],{"trials":1063,"activeCount":65},[],{"trials":1065,"activeCount":65},[],{"trials":1067,"activeCount":65},[],{"trials":1069,"activeCount":65},[],{"trials":1071,"activeCount":65},[1072],{"nctId":1073,"briefTitle":1074,"status":310,"phases":1075,"primaryCompletion":1076,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1080},"NCT03423641","An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C",[],"2017-12-31","2011-01-01",33808,[316],[1058],{"intervention":1082,"totalTrials":61,"cells":1083},"clofazamine",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1085,"activeCount":65},[],{"trials":1087,"activeCount":65},[],{"trials":1089,"activeCount":65},[],{"trials":1091,"activeCount":65},[],{"trials":1093,"activeCount":65},[],{"trials":1095,"activeCount":65},[1096],{"nctId":1097,"briefTitle":1098,"status":1099,"phases":1100,"conditions":1101,"interventions":1103},"NCT00852345","Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy","NO_LONGER_AVAILABLE",[],[1102],"Leprosy",[1082],{"intervention":1105,"totalTrials":61,"cells":1106},"Whole Genome Sequencing",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1115,"NA":1117},{"trials":1108,"activeCount":65},[],{"trials":1110,"activeCount":65},[],{"trials":1112,"activeCount":65},[],{"trials":1114,"activeCount":65},[],{"trials":1116,"activeCount":65},[],{"trials":1118,"activeCount":65},[1119],{"nctId":1120,"briefTitle":1121,"status":310,"phases":1122,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1129},"NCT01902901","Clinical Implementation of Carrier Status Using Next Generation Sequencing",[58],"2017-01","2018-05","2014-01",384,[1128],"Genetic Disorders",[1105,1130],"Carrier status testing",{"intervention":1130,"totalTrials":61,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1134,"activeCount":65},[],{"trials":1136,"activeCount":65},[],{"trials":1138,"activeCount":65},[],{"trials":1140,"activeCount":65},[],{"trials":1142,"activeCount":65},[],{"trials":1144,"activeCount":65},[1145],{"nctId":1120,"briefTitle":1121,"status":310,"phases":1146,"primaryCompletion":1123,"completion":1124,"start":1125,"enrollment":1126,"conditions":1147,"interventions":1148},[58],[1128],[1105,1130],{"intervention":1150,"totalTrials":61,"cells":1151},"Ciprofloxacin",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1160,"NA":1162},{"trials":1153,"activeCount":65},[],{"trials":1155,"activeCount":65},[],{"trials":1157,"activeCount":65},[],{"trials":1159,"activeCount":65},[],{"trials":1161,"activeCount":65},[],{"trials":1163,"activeCount":65},[1164],{"nctId":1165,"briefTitle":1166,"status":310,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1125,"enrollment":16,"conditions":1169,"interventions":1171},"NCT01929460","A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration",[58],"2014-11",[1170],"Pancreatic Cysts",[1150],{"intervention":1173,"totalTrials":61,"cells":1174},"SU",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1176,"activeCount":65},[],{"trials":1178,"activeCount":65},[],{"trials":1180,"activeCount":65},[],{"trials":1182,"activeCount":65},[],{"trials":1184,"activeCount":65},[],{"trials":1186,"activeCount":65},[1187],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1190,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1197},"NCT05073692","Comparison of Type 2 Diabetes Pharmacotherapy Regimens",[],"2024-12-31","2025-03-12","2021-07-01",241981,[1196,32],"Type 2 Diabetes Mellitus",[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],"DPP4","SGLT2i","GLP-1RA","SGLT2i or GLP-1RA","Linagliptin","Exenatide","Liraglutide","Empagliflozin","Glimepiride","Glipizide","SU or DPP4",{"intervention":1198,"totalTrials":61,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1221},{"trials":1212,"activeCount":65},[],{"trials":1214,"activeCount":65},[],{"trials":1216,"activeCount":65},[],{"trials":1218,"activeCount":65},[],{"trials":1220,"activeCount":65},[],{"trials":1222,"activeCount":65},[1223],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1224,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1225,"interventions":1226},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1199,"totalTrials":61,"cells":1228},{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1230,"activeCount":65},[],{"trials":1232,"activeCount":65},[],{"trials":1234,"activeCount":65},[],{"trials":1236,"activeCount":65},[],{"trials":1238,"activeCount":65},[],{"trials":1240,"activeCount":65},[1241],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1242,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1243,"interventions":1244},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1200,"totalTrials":61,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1248,"activeCount":65},[],{"trials":1250,"activeCount":65},[],{"trials":1252,"activeCount":65},[],{"trials":1254,"activeCount":65},[],{"trials":1256,"activeCount":65},[],{"trials":1258,"activeCount":65},[1259],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1260,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1261,"interventions":1262},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1201,"totalTrials":61,"cells":1264},{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1266,"activeCount":65},[],{"trials":1268,"activeCount":65},[],{"trials":1270,"activeCount":65},[],{"trials":1272,"activeCount":65},[],{"trials":1274,"activeCount":65},[],{"trials":1276,"activeCount":65},[1277],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1278,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1279,"interventions":1280},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1202,"totalTrials":61,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1291,"NA":1293},{"trials":1284,"activeCount":65},[],{"trials":1286,"activeCount":65},[],{"trials":1288,"activeCount":65},[],{"trials":1290,"activeCount":65},[],{"trials":1292,"activeCount":65},[],{"trials":1294,"activeCount":65},[1295],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1296,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1297,"interventions":1298},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1203,"totalTrials":61,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1309,"NA":1311},{"trials":1302,"activeCount":65},[],{"trials":1304,"activeCount":65},[],{"trials":1306,"activeCount":65},[],{"trials":1308,"activeCount":65},[],{"trials":1310,"activeCount":65},[],{"trials":1312,"activeCount":65},[1313],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1314,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1315,"interventions":1316},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1204,"totalTrials":61,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1327,"NA":1329},{"trials":1320,"activeCount":65},[],{"trials":1322,"activeCount":65},[],{"trials":1324,"activeCount":65},[],{"trials":1326,"activeCount":65},[],{"trials":1328,"activeCount":65},[],{"trials":1330,"activeCount":65},[1331],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1332,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1333,"interventions":1334},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1205,"totalTrials":61,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1338,"activeCount":65},[],{"trials":1340,"activeCount":65},[],{"trials":1342,"activeCount":65},[],{"trials":1344,"activeCount":65},[],{"trials":1346,"activeCount":65},[],{"trials":1348,"activeCount":65},[1349],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1350,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1351,"interventions":1352},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1206,"totalTrials":61,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1365},{"trials":1356,"activeCount":65},[],{"trials":1358,"activeCount":65},[],{"trials":1360,"activeCount":65},[],{"trials":1362,"activeCount":65},[],{"trials":1364,"activeCount":65},[],{"trials":1366,"activeCount":65},[1367],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1368,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1369,"interventions":1370},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1207,"totalTrials":61,"cells":1372},{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1381,"NA":1383},{"trials":1374,"activeCount":65},[],{"trials":1376,"activeCount":65},[],{"trials":1378,"activeCount":65},[],{"trials":1380,"activeCount":65},[],{"trials":1382,"activeCount":65},[],{"trials":1384,"activeCount":65},[1385],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1386,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1387,"interventions":1388},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1208,"totalTrials":61,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1392,"activeCount":65},[],{"trials":1394,"activeCount":65},[],{"trials":1396,"activeCount":65},[],{"trials":1398,"activeCount":65},[],{"trials":1400,"activeCount":65},[],{"trials":1402,"activeCount":65},[1403],{"nctId":1188,"briefTitle":1189,"status":310,"phases":1404,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1405,"interventions":1406},[],[1196,32],[1173,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1206,1208,1203],{"intervention":1408,"totalTrials":61,"cells":1409},"Provera",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1411,"activeCount":65},[],{"trials":1413,"activeCount":65},[],{"trials":1415,"activeCount":65},[],{"trials":1417,"activeCount":65},[],{"trials":1419,"activeCount":65},[],{"trials":1421,"activeCount":65},[1422],{"nctId":1423,"briefTitle":1424,"status":310,"phases":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1432},"NCT00350480","Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial",[58],"2005-06","2003-04",240,[1430,1431],"Uterine Hemorrhage","Menorrhagia",[1408,1433],"Combination Birth Control pills",{"intervention":1433,"totalTrials":61,"cells":1435},{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1437,"activeCount":65},[],{"trials":1439,"activeCount":65},[],{"trials":1441,"activeCount":65},[],{"trials":1443,"activeCount":65},[],{"trials":1445,"activeCount":65},[],{"trials":1447,"activeCount":65},[1448],{"nctId":1423,"briefTitle":1424,"status":310,"phases":1449,"completion":1426,"start":1427,"enrollment":1428,"conditions":1450,"interventions":1451},[58],[1430,1431],[1408,1433],{"intervention":1453,"totalTrials":61,"cells":1454},"Flublok Quadrivalent",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1456,"activeCount":65},[],{"trials":1458,"activeCount":65},[],{"trials":1460,"activeCount":65},[],{"trials":1462,"activeCount":65},[],{"trials":1464,"activeCount":65},[],{"trials":1466,"activeCount":65},[1467],{"nctId":1468,"briefTitle":1469,"status":310,"phases":1470,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1481},"NCT03694392","Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years",[],"2021-04-09","2022-12-31","2018-09-16",2776278,[1476,911,1477,1478,1479,1480],"Influenza","Lower Respiratory Tract Infection","Acute Myocardial Infarction","Congestive Heart Failure","Stroke",[1453,1482],"Standard Dose Inactivated Influenza Vaccine",{"intervention":1482,"totalTrials":61,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1486,"activeCount":65},[],{"trials":1488,"activeCount":65},[],{"trials":1490,"activeCount":65},[],{"trials":1492,"activeCount":65},[],{"trials":1494,"activeCount":65},[],{"trials":1496,"activeCount":65},[1497],{"nctId":1468,"briefTitle":1469,"status":310,"phases":1498,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":1474,"conditions":1499,"interventions":1500},[],[1476,911,1477,1478,1479,1480],[1453,1482],{"intervention":1502,"totalTrials":61,"cells":1503},"Antidepressants",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1510,"PHASE4":1512,"NA":1514},{"trials":1505,"activeCount":65},[],{"trials":1507,"activeCount":65},[],{"trials":1509,"activeCount":65},[],{"trials":1511,"activeCount":65},[],{"trials":1513,"activeCount":65},[],{"trials":1515,"activeCount":65},[1516],{"nctId":1517,"briefTitle":1518,"status":310,"phases":1519,"primaryCompletion":1520,"completion":1520,"start":1521,"enrollment":1522,"conditions":1523,"interventions":1525},"NCT00158275","Combined Interventions for Treating Depression and Chronic Back Pain",[58],"2006-08","2004-10",71,[1524,18],"Back Pain",[1502],{"intervention":1527,"totalTrials":61,"cells":1528},"Adjuvanted Quadrivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1530,"activeCount":65},[],{"trials":1532,"activeCount":65},[],{"trials":1534,"activeCount":65},[],{"trials":1536,"activeCount":65},[],{"trials":1538,"activeCount":65},[],{"trials":1540,"activeCount":65},[1541],{"nctId":1542,"briefTitle":1543,"status":149,"phases":1544,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1552},"NCT06029933","Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years",[],"2025-05","2026-05","2023-08-17",960000,[1476,1550,1551],"Community-acquired Pneumonia","Cardiovascular Events",[1527,1553],"High-Dose Quadrivalent Inactivated Influenza Vaccine",{"intervention":1553,"totalTrials":61,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1557,"activeCount":65},[],{"trials":1559,"activeCount":65},[],{"trials":1561,"activeCount":65},[],{"trials":1563,"activeCount":65},[],{"trials":1565,"activeCount":65},[],{"trials":1567,"activeCount":65},[1568],{"nctId":1542,"briefTitle":1543,"status":149,"phases":1569,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":1548,"conditions":1570,"interventions":1571},[],[1476,1550,1551],[1527,1553],{"intervention":1573,"totalTrials":61,"cells":1574},"Ergocalciferol supplementation",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1581,"PHASE4":1583,"NA":1585},{"trials":1576,"activeCount":65},[],{"trials":1578,"activeCount":65},[],{"trials":1580,"activeCount":65},[],{"trials":1582,"activeCount":65},[],{"trials":1584,"activeCount":65},[],{"trials":1586,"activeCount":65},[1587],{"nctId":1588,"briefTitle":1589,"status":285,"phases":1590,"primaryCompletion":555,"completion":555,"start":1591,"enrollment":1592,"conditions":1593,"interventions":1595},"NCT01263028","Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose",[58],"2010-08",6,[1594],"Chronic Kidney Disease Stages 3-5",[1573],{"intervention":1597,"totalTrials":61,"cells":1598},"Fenofibrate 54mg",{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1600,"activeCount":65},[],{"trials":1602,"activeCount":65},[],{"trials":1604,"activeCount":65},[],{"trials":1606,"activeCount":65},[],{"trials":1608,"activeCount":65},[],{"trials":1610,"activeCount":65},[1611],{"nctId":1612,"briefTitle":1613,"status":310,"phases":1614,"primaryCompletion":1615,"completion":1615,"start":1616,"enrollment":1053,"conditions":1617,"interventions":1619},"NCT01280604","Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy",[58],"2013-01","2010-10",[1618],"Hyperlipidemias",[1597],{"intervention":1621,"totalTrials":61,"cells":1622},"2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine",{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1624,"activeCount":65},[],{"trials":1626,"activeCount":65},[],{"trials":1628,"activeCount":65},[],{"trials":1630,"activeCount":65},[],{"trials":1632,"activeCount":65},[],{"trials":1634,"activeCount":65},[1635],{"nctId":1636,"briefTitle":1637,"status":310,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1643},"NCT00158665","A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age",[58],"2004-12","2004-08",280,[1476],[1621],{"intervention":1645,"totalTrials":61,"cells":1646},"ipratropium",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1648,"activeCount":65},[],{"trials":1650,"activeCount":65},[],{"trials":1652,"activeCount":65},[],{"trials":1654,"activeCount":65},[],{"trials":1656,"activeCount":65},[],{"trials":1658,"activeCount":65},[1659],{"nctId":1660,"briefTitle":1661,"status":310,"phases":1662,"completion":1663,"start":1664,"enrollment":314,"conditions":1665,"interventions":1667},"NCT00371527","Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease",[58],"2004-01","2002-10",[1666],"Bronchitis",[1645]]